The Clorox Company
CLXFinancial Snapshot
ticker: CLX step: 04 generated: 2026-05-13 source: quick-research
The Clorox Company (CLX) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue | $7.10B | $7.39B | $7.09B | -4.0% |
| Gross Margin | ~38% | ~37% | ~44% | |
| Operating Margin | ~9% | ~3% | ~6% | |
| Net Income | $462M | $149M | $280M | +88% |
| EPS (diluted) | ~$3.72 | ~$1.20 | ~$2.25 | +88% |
FY2022–2023 were deeply impacted by commodity cost inflation (resins, diesel, pulp) and the catastrophic ERP implementation failure that caused supply-chain breakdowns and a 17% organic sales decline at peak disruption. FY2024 showed recovery — gross margin expanded to ~44% as commodity costs normalized and pricing actions flowed through. FY2025 revenue reached $7.1B with EPS recovery continuing; Health & Wellness segment grew 8.5% YoY.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$800M |
| Free Cash Flow | ~$650M |
| Capital Expenditures | ~$150M |
| Cash & Equivalents | ~$350M |
| Total Debt | ~$2.8B |
FCF recovered strongly as gross margins normalized. Dividend currently $1.22/quarter ($4.88/year), yielding ~4.8% — maintained through the ERP crisis, signaling management confidence. Debt elevated but manageable given FCF generation.
Key Ratios (approximate)
- P/E: ~30–35x (trailing, on recovering EPS) | EV/EBITDA: ~18x | Dividend Yield: ~4.8%
- Revenue Growth (FY2024): -4.0% | FY2025: ~flat to slight positive
- Return on Invested Capital: ~35%+ (brand moat indicator)
- Bleach market share: ~61% U.S.
Growth Profile
Clorox is a slow-growth staples compounder under normal conditions (2–4% organic growth) disrupted by two major shocks: FY2022 commodity inflation and FY2023–2024 ERP disaster. The recovery path involves: (1) fill rate normalization (target 92%+ by early 2026), (2) gross margin recovery toward 44–45% as commodity headwinds ease, (3) market share recapture in categories where stockouts caused switching. FY2025 and FY2026 should show above-trend EPS growth driven by recovery, not fundamental acceleration. The structural long-term thesis is brand moat + pricing power in essential categories.
Forward Estimates
- FY2026: Revenue growth of 2–4% organic; EPS recovery toward $6–7 adjusted as margins stabilize
- Dividend: $4.88/year (FY2025); consistent annual increases expected
- Analyst consensus: Mixed — majority Hold/Neutral; some Underweight (JPMorgan downgrade April 2026 citing private-label pressure and consumer weakness)
- Private-label risk: Key watch item — share erosion in cleaning products vs. store brands at Walmart/Target
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $CLX.